Orchid to acquire US-based Karalex

“With this acquisition,Orchid has established its presence in the generic sales and marketing area. This acquisition will provide a strong commercial US-based sales capability to Orchid,paving the way for synergistic returns from our upcoming and long-term strategic generic pharmaceuticals pipeline comprising key first-to-file and Paragraph-IV products,” Orchid Chemicals Managing Director,K Raghavendra Rao,told reporters here.

This acquisition will help the Indian generic drug-maker to directly sell its generic products in the US market.

It will add USD 20-million to the company’s revenue in the current fiscal year,” Rao said.

This move also endows Orchid,for the first time,with a complete end-to-end coverage capability of the entire generic pharmaceutical business cycle from product development to product sales and would enable the company to internalise value.